PHAXIAM Therapeutics S.A. (PHXM.PA)
EUR 0.72
(6.19%)
EUR 0.72
(6.19%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.32 Million EUR | -107.54% |
| 2022 | 3.73 Million EUR | 412.36% |
| 2021 | -1.19 Million EUR | 5.97% |
| 2020 | -1.27 Million EUR | -219.31% |
| 2019 | 1.06 Million EUR | 233.88% |
| 2018 | -797 Thousand EUR | -50.38% |
| 2017 | -530 Thousand EUR | -24.12% |
| 2016 | -427 Thousand EUR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 176.5 Thousand EUR | 0.0% |
| 2024 Q1 | 546.5 Thousand EUR | 43.06% |
| 2023 Q3 | 197 Thousand EUR | 261.48% |
| 2023 Q1 | 139 Thousand EUR | -96.09% |
| 2023 FY | -282 Thousand EUR | -107.54% |
| 2023 Q4 | 382 Thousand EUR | 93.91% |
| 2023 Q2 | -122 Thousand EUR | -187.77% |
| 2022 Q2 | -4.29 Million EUR | 0.0% |
| 2022 Q4 | 3.55 Million EUR | 656.81% |
| 2022 Q3 | 470 Thousand EUR | 110.96% |
| 2022 FY | 3.73 Million EUR | 412.36% |
| 2021 Q2 | -2.49 Million EUR | 0.0% |
| 2021 Q4 | -2.88 Million EUR | 0.0% |
| 2021 FY | -1.19 Million EUR | 5.97% |
| 2020 Q4 | -2.48 Million EUR | 0.0% |
| 2020 FY | -1.27 Million EUR | -219.31% |
| 2020 Q2 | -2.43 Million EUR | 0.0% |
| 2019 Q4 | -3.12 Million EUR | 0.0% |
| 2019 FY | 1.06 Million EUR | 233.88% |
| 2018 FY | -797 Thousand EUR | -50.38% |
| 2017 FY | -530 Thousand EUR | -24.12% |
| 2016 FY | -427 Thousand EUR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Nicox S.A. | -11.5 Million EUR | 111.527% |
| European Medical Solutions | 13.51 Million EUR | 90.186% |
| FERMENTALG | 535 Thousand EUR | -147.85% |
| argenx SE | 925.49 Million EUR | 99.857% |
| BioSenic S.A. | 543 Thousand EUR | -144.199% |
| Celyad Oncology SA | 33 Thousand EUR | -3918.182% |
| Hyloris Pharmaceuticals SA | 1.99 Million EUR | 33.501% |
| Onward Medical N.V. | -14.81 Million EUR | 108.949% |
| Oxurion NV | 104 Thousand EUR | -1175.0% |
| Financière de Tubize SA | -2.02 Million EUR | 165.334% |
| UCB SA | 3.34 Billion EUR | 99.96% |